Jacobs Levy Equity Management, Inc Ventyx Biosciences, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 568,479 shares of VTYX stock, worth $1.34 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
568,479
Previous 475,726
19.5%
Holding current value
$1.34 Million
Previous $1.1 Million
12.84%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Deerfield Management Company, L.P. (Series C) New York, NY6.72MShares$15.8 Million0.27% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$11.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$8.15 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.45 Million0.03% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $133M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...